Background-Sphingosine-1-phosphate (S1P) signaling is a central regulator of resistance artery tone. Therefore, S1P levels need to be tightly controlled through the delicate interplay of its generating enzyme sphingosine kinase 1 and its functional antagonist S1P phosphohydrolase-1. The intracellular localization of S1P phosphohydrolase-1 necessitates the import of extracellular S1P into the intracellular compartment before its degradation. The present investigation proposes that the cystic fibrosis transmembrane conductance regulator transports extracellular S1P and hence modulates microvascular S1P signaling in health and disease. Methods and Results-In cultured murine vascular smooth muscle cells in vitro and isolated murine mesenteric and posterior cerebral resistance arteries ex vivo, the cystic fibrosis transmembrane conductance regulator (1) is critical for S1P uptake;
S phingosine-1-phosphate (S1P) is a ubiquitous signaling mediator that directs a diverse array of biological processes. 1 In the microcirculation, S1P is a potent vasoconstrictor and a central mediator regulating myogenic tone. [2] [3] [4] [5] This confers S1P signaling with significant importance in the control of blood flow autoregulation, tissue perfusion, and systemic blood pressure.
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The potent and pleiotropic effects of S1P are confined both spatially and temporally 6 ; however, the molecular mecha-nisms limiting S1P bioavailability are not completely understood. We have demonstrated that S1P phosphohydrolase-1 (SPP1), an intracellular enzyme primarily localized to the endoplasmic reticulum, 7,8 degrades extracellular S1P. 3 As a consequence, we concluded that an S1P "import" mechanism must be present in vascular smooth muscle cells. Boujaoude et al 9 have provided indirect evidence that the cystic fibrosis transmembrane conductance regulator (CFTR) could act as this S1P transporter and thereby limit S1P receptor-mediated effects. Accordingly, we have observed that CFTR inhibition specifically enhances responses known to rely on S1P in skeletal muscle resistance arteries. 3 Proper CFTR function requires the orchestrated regulation of expression, localization, and gating. On the basis of our proposed model that CFTR transports extracellular S1P across the plasma membrane for degradation, the disruption of any of these aspects would be expected to affect S1P signaling. This leads us to speculate that CFTR dysfunction could play a causal role in pathological conditions that are associated with altered S1P signaling. 10 -12 The prominent enhancement of S1P signaling in resistance arteries under the condition of heart failure (HF) 4,5 is a prime example advanced in the present investigation.
In the present study, we demonstrate that an inverse relationship between microvascular CFTR activity and S1P signaling is manifest both in well-defined S1P-dependent vasomotor responses and myogenic tone 2, 13, 14 and in mice with HF, a disease model in which S1P is known to mediate enhanced peripheral vascular resistance. 4 
Methods
This investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (publication No. 85-23, revised 1996) . All animal care and experimental protocols were approved by the institutional animal care and use committees at the University of Toronto and the University Health Network, Toronto, and were conducted in accordance with Canadian animal protection laws.
Animals
Wild-type mice (aged 2-3 months; C57BL6) were purchased commercially from Charles River Laboratories (Montreal, Quebec, Canada). Tumor necrosis factor-␣ (TNF-␣) knockout mice (TNF␣ Ϫ/Ϫ ) 15 were purchased commercially from Taconic Laboratories (Hudson, NY). CFTR knockout mice (CFTR Ϫ/Ϫ ) 16 were obtained from an established colony maintained at the Hospital for Sick Children, Toronto. All mice were housed under a standard 12-hour/12-hour light/dark cycle, were fed normal chow, and had access to water ad libitum.
Preparation of Cultured Primary Mesenteric Artery Smooth Muscle Cells
Mesenteric artery segments were isolated, cut into small pieces, and digested with trypsin, collagenase, and elastase. The resulting cell suspension was washed several times in phosphate-buffered saline and plated in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 1% penicillin-streptomycin. Cell cultures were maintained at 37°C with 5% CO 2 split at a seeding density of 10 6 cells. Immunostaining for ␣-actin, positive polymerase chain reaction results for myocardin and MyoD, and negative polymerase chain reaction results for endothelial NO synthase confirmed smooth muscle cell identity.
Fluorescence-Activated Cell Sorting-Based Measurement of Fluorescein Isothiocyanate-S1P Uptake
A fluorescence-activated cell sorting (FACS)-based approach to semiquantitatively measure the uptake of S1P-fluorescein isothiocyanate (FITC) has been published previously. 17 Briefly, cell monolayers (treated or untreated) were incubated with 1 mol/L S1P-FITC for 60 minutes; the cells were then detached by trypsinization, washed twice with ice-cold phosphate-buffered saline, filtered through a 70-m cell strainer, and analyzed with the use of the Becton-Dickinson FACS Canto operated by FACS DIVA version 6.1 software. Cell monolayers treated with unlabeled S1P served as background controls. The analysis procedure determined the median fluorescence intensity (arbitrary units) of each cell population, which is a measure of uptake.
Isolation and Functional Assessment of Cerebral Arteries
Experiments utilized both mouse posterior cerebral arteries (PCAs) 5 and mesenteric arteries. 4 After careful dissection, artery segments were cannulated on glass micropipettes, stretched to their in vivo lengths, and pressurized to 45 mm Hg. All functional experiments were conducted in 3-(N-morpholino)propanesulfonic acid (MOPS)buffered saline at 37°C with no perfusion.
To measure myogenic responses, vessels were subjected to stepwise increases in transmural pressure (increments of 20 mm Hg) from 20 to 100 mm Hg. At each pressure step, vessel diameter (dia active ) was measured once a steady state was reached (3-5 minutes). Myogenic tone was calculated as the percent constriction in relation to the maximal diameter at each respective transmural pressure, as follows: tone (% of dia max )ϭ[(dia max Ϫdia active )/dia max ]ϫ100, where dia active is the vessel diameter in MOPS containing Ca 2ϩ , and dia max is the diameter in Ca 2ϩ -free MOPS.
Receptor-stimulated vasomotor responses were determined with the same calculation, but in this case, dia active represents the vessel diameter at steady state after application of the given agent, and dia max represents the maximal diameter (measured under Ca 2ϩ -free conditions) at 45 mm Hg. Complete details are provided in the online-only Data Supplement.
Myocardial Infarction
HF in mice was induced by experimental myocardial infarction produced by surgical ligation of the left anterior descending (LAD) coronary artery. 4 Briefly, mice were anesthetized with isoflurane, intubated with a 20-gauge angiocatheter, and ventilated with room air. Under sterile conditions, the thorax and pericardium were opened, and the LAD was permanently ligated with 7-0 silk suture (Deknatel; Fall River). In sham-operated controls, the thorax and pericardium were opened, but the LAD was not ligated. After the procedure, the chest was closed, and the mice were extubated on spontaneous respiration. Cerebral arteries were isolated 4 to 6 weeks after myocardial infarction. As described, 4 HF mice develop enlarged hearts, congested lungs, and reduced cardiac output and blood pressure, with elevated peripheral resistance. All of these parameters remained normal in sham-operated controls.
Western Blots, Reverse Transcription Polymerase Chain Reaction, and Cell Proliferation Assessment
Standard biochemical procedures were utilized for experiments involving reverse transcription polymerase chain reaction and Western blots, including the fractionation of cellular lysates procedure in the latter case. A standard cell-counting approach was used to assess cell proliferation. Methodological details are provided in the onlineonly Data Supplement.
Statistical Analysis
All data are expressed as meanϮSEM, where n is the number of independent experiments. A nonparametric Wilcoxon test with computation of exact P values was utilized for the comparison of 2 independent groups. For comparison of multiple independent groups, a nonparametric 1-way ANOVA (Kruskal-Wallis) followed by a Wilcoxon test with exact P value computation as a post hoc test for pairwise comparisons was used (because this was exploratory, we did not adjust for multiple comparisons). For the assessment of myogenic responses and dose-response relationships, data were analyzed with a 2-way repeated-measures ANOVA; if a significant effect of treatment/genotype was observed, the Wilcoxon test with exact P value computation was employed post hoc to assess the differences. Differences were considered significant at error probabilities of PϽ0.05. A Pearson correlation analysis was used for correlative assessments.
Results

CFTR Is Essential for S1P Import Into Vascular Smooth Muscle Cells
We first confirmed the expression of CFTR mRNA throughout the mouse vascular tree, including conduit and resistance arteries ( Figure I in the online-only Data Supplement). Expression of CFTR protein was confirmed in mouse posterior cerebral and mesenteric arteries and in primary vascular smooth muscle cells (VSMCs) derived from mouse mesenteric arteries ( Figure 1A) .
Using a standard FACS assay and a pharmacological CFTR inhibitor [CFTR(inh)-172], we next demonstrated CFTR-dependent accumulation of FITC-labeled S1P (FITC-S1P) in VSMCs ( Figure 1B and 1C) . Control experiments demonstrated that coincubating unlabeled and FITC-labeled S1P significantly inhibited FITC-S1P uptake ( Figure II in the online-only Data Supplement). FITC-S1P uptake was absent in VSMCs isolated from mice lacking CFTR (CFTR Ϫ/Ϫ ; Figure  1C ), a deficiency rescued by expression of a green fluorescent protein (GFP)-tagged CFTR construct (GFP-CFTR wt ) and then abolished again by CFTR(inh)-172 ( Figure 1D ).
To more directly link S1P transport to CFTR expression and membrane localization, we studied immortalized baby hamster kidney cells, which possess a minimal endogenous level of CFTR. Baby hamster kidney cells exhibited a low Figure 1 . The cystic fibrosis transmembrane conductance regulator (CFTR) mediates cellular fluorescein isothiocyanate (FITC)sphingosine-1-phosphate (S1P) uptake. A, Western blots confirm CFTR protein expression in isolated mouse cerebral and mesenteric arteries, as well as primary vascular smooth muscle cells (VSMCs) isolated from mouse mesenteric arteries. No CFTR signal was detected from mesenteric VSMCs isolated from CFTR knockout (CFTR Ϫ/Ϫ ) mice. The blots displayed are representative of at least 3 separate experiments. B, A standard fluorescence-activated cell sorting analysis technique reveals a shift in the median fluorescence intensity at 525 nm for VSMCs incubated with FITC-S1P compared with cells incubated with unlabeled S1P (background [Bkgd]). This median shift represents a measure of FITC-S1P uptake. C, In wild-type littermate VSMCs (CFTR ϩ/ϩ ), the median fluorescence intensity shift (nϭ6) is abolished by CFTR inhibition [100 nmol/L CFTR(inh)-172 for 30 minutes; nϭ5]. In VSMCs isolated from CFTR knockout mice, no shift in median fluorescence intensity is observed after FITC-S1P treatment (nϭ6), nor is there an effect of CFTR inhibition (nϭ5). Con indicates control. D, The S1P uptake deficit in CFTR Ϫ/Ϫ VSMCs was rescued by transfecting the cells with a wild-type CFTR construct (CFTR wt ; nϭ6); the rescued S1P uptake was abolished by CFTR inhibition (nϭ5). E, In baby hamster kidney (BHK) cells, stable expression of CFTR wt significantly increased S1P uptake compared with nontransfected cells (nϭ4). F, Maintaining BHK cells that express CFTR ⌬F508 at 27°C for 24 hours (a procedure that increases plasma membrane abundance of CFTR) also significantly increased S1P uptake (nϭ6). *PϽ0.05 for multiple, unpaired comparisons within each genotype in C; multiple, unpaired comparisons in D; and single, unpaired comparisons in E and F. E and F display data normalized to their respective backgrounds.
level of FITC-S1P uptake, which was enhanced by stable expression of CFTR wt ( Figure 1E ; the absolute values for all normalized FITC-S1P uptake data are supplied in Table I in the online-only Data Supplement). In baby hamster kidney cells stably expressing a temperature-sensitive CFTR mutant (CFTR ⌬F508 ), FITC-S1P uptake could only be increased if culture conditions permitted proper membrane localization of CFTR (27°C; Figure 1F ). 18 Under conditions causing retention of CFTR in the endoplasmic reticulum (37°C for 24 hours), 18 FITC-S1P uptake was not enhanced by the expression of CFTR ⌬F508 ( Figure 1F ).
CFTR Modulates Effects of S1P on Cells and Vessels
We next explored whether CFTR-dependent S1P transport affects 2 well-documented receptor-dependent responses to exogenous S1P. 3, 19 At the cellular level, VSMCs derived from wild-type (CFTR ϩ/ϩ ) mesenteric arteries possessed a higher rate of proliferation than those isolated from CFTR knockout mice (CFTR Ϫ/Ϫ ; see control bars in Figure 2A versus 2B; PϽ0.05). Although treatment with S1P (100 nmol/L) inhibited cell proliferation in both genotypes, pharmacological inhibition of CFTR only enhanced the Figure 2 . The cystic fibrosis transmembrane conductance regulator (CFTR) modulates sphingosine-1-phosphate (S1P)-dependent responses in cultured vascular smooth muscle cells and isolated arteries. A, S1P (100 nmol/L) significantly inhibits wild-type (CFTR ϩ/ϩ ) vascular smooth muscle cell proliferation, an effect that is enhanced by CFTR inhibition [100 nmol/L CFTR(inh)-172; nϭ5 for all groups]. B, CFTR knockout (CFTR Ϫ/Ϫ ) vascular smooth muscle cell proliferation is lower under control (con) conditions than CFTR ϩ/ϩ vascular smooth muscle cells (PϽ0.05 comparing white bars in A and B; nϭ5). S1P inhibits cell proliferation in CFTR Ϫ/Ϫ vascular smooth muscle cells; however, CFTR inhibition has no further effect (nϭ5). C, S1P-stimulated vasoconstriction is stronger in posterior cerebral arteries isolated from CFTR Ϫ/Ϫ compared with CFTR ϩ/ϩ littermate controls (nϭ6 for both groups). Posterior cerebral artery responses to phenylephrine (D) and acetylcholine (E) are similar in the 2 genotypes (nϭ4 for CFTR ϩ/ϩ ; nϭ3 for CFTR Ϫ/Ϫ ). F, Posterior cerebral artery myogenic tone is stronger at all transmural pressures Ͼ20 mm Hg (ie, 40 -100 mm Hg); a similar pattern is observed for mesenteric arteries (G) (for both cerebral and mesenteric arteries: nϭ6 for CFTR ϩ/ϩ ; nϭ8 for CFTR Ϫ/Ϫ ). The enhanced myogenic tone in CFTR Ϫ/Ϫ cerebral (F) and mesenteric (G) arteries is abolished by S1P 2 receptor inhibition (1 mol/L JTE013; 30 minutes; nϭ4 for both artery types). Maximal vessel diameters at 45 mm Hg (dia max ) were as follows: posterior cerebral artery CFTR ϩ/ϩ 166Ϯ8 m (nϭ8), posterior cerebral artery CFTR Ϫ/Ϫ 162Ϯ5 m (nϭ6), PϭNS; and mesenteric CFTR ϩ/ϩ 240Ϯ11 m (nϭ8), mesenteric CFTR Ϫ/Ϫ 301Ϯ34 m (nϭ6), PϭNS. In A and B, *PϽ0.05 relative to control; ϩPϽ0.05 relative to S1P for multiple, unpaired comparisons; in C through E, *PϽ0.05 after 2-way repeated-measures ANOVA; in F and G, *PϽ0.05 relative to the CFTR ϩ/ϩ genotype after 2-way ANOVA.
antiproliferative effects of S1P in CFTR ϩ/ϩ cells ( Figure  2A and 2B), indicating target specificity of CFTR(inh)-172 and supporting the ability of CFTR to limit S1P-dependent effects.
At the organ level, dose-dependent S1P vasoconstriction of mouse PCAs was more potent in CFTR Ϫ/Ϫ versus CFTR ϩ/ϩ PCAs ( Figure 2C ). Importantly, CFTR Ϫ/Ϫ and CFTR ϩ/ϩ PCAs did not differ in their vasomotor responses to phenylephrine ( Figure 2D ) or acetylcholine ( Figure 2E ).
To assess the functional relevance of CFTR to the regulation of endogenous S1P signaling, we examined pressureinduced myogenic vasoconstriction, a complex integrated response modulated prominently by S1P. 2 PCAs isolated from CFTR Ϫ/Ϫ mice displayed stronger myogenic vasoconstriction at all transmural pressures Ͼ40 mm Hg (ie, 60 -100 mm Hg) compared with PCAs from CFTR ϩ/ϩ littermate controls ( Figure 2F) . These effects were not limited to cerebral vessels because mesenteric arteries displayed similar results ( Figure 2G ). To confirm the full dependence of myogenic responses on S1P signaling, pressure-induced vasoconstriction in both cerebral and mesenteric CFTR Ϫ/Ϫ vessels was abolished by the putative S1P 2 receptor antagonist JTE013 (Figure 2F and 2G ).
CFTR Expression Is Diminished in HF
Alterations in S1P signaling are common to several pathological processes. Indeed, we have demonstrated recently that mesenteric and cremasteric artery myogenic responses are significantly enhanced in a post-myocardial infarction model of HF as a result of augmented S1P signaling. 4 Consistent with an inverse relationship between CFTR and S1P signal-ing, we found marked reductions in CFTR mRNA and protein in PCAs isolated from mice with HF (4 -6 weeks after myocardial infarction) versus sham-operated controls ( Figure  3A and Figure IIIA in the online-only Data Supplement). Similar reductions in CFTR mRNA (28Ϯ11%; nϭ15; PϽ0.05) and protein (42Ϯ5%; nϭ7; PϽ0.05) were observed in mesenteric arteries isolated from mice with HF ( Figure  IIIB and IIIC in the online-only Data Supplement). In both vascular beds, CFTR expression correlated negatively with infarct size ( Figure 3B and Figure IV in the online-only Data Supplement). As shown in Figure 3C through 3E, HF did not affect expression levels of sphingosine kinase 1, SPP1, or the S1P 2 receptor mRNA.
Expression and Localization of CFTR Are Regulated by TNF-␣
Because HF is known to increase TNF-␣ 20 -22 and TNF-␣ is known to augment S1P signaling, [23] [24] [25] we next explored whether TNF-␣ underlies reduced expression levels of CFTR in HF. As we have demonstrated previously, 4 mice with HF displayed evidence of fluid retention and organ congestion (manifested as increased body, heart, lung, and liver weights and an increase in the ratio of heart to body weight) and decreased cardiac function ( Table II in . Heart failure (HF) downregulates the cystic fibrosis transmembrane conductance regulator (CFTR) but not sphingosine-1phosphate (S1P) signaling components. HF (4 -6 weeks after myocardial infarction) is associated with the downregulation of posterior cerebral artery CFTR protein expression (nϭ4) (A), which negatively correlated with the extent of the myocardial infarction (B). C through E, HF does not affect the mRNA expression of mesenteric artery sphingosine kinase 1 (SphK1; nϭ12), S1P phosphohydrolase 1 (SPP1; nϭ7), or the S1P 2 receptor subtype (S1P 2 R; nϭ6). *PϽ0.05 for single, unpaired comparisons. Supplement). At the vascular level, this treatment protocol normalized myogenic tone and vasomotor responses to exogenous S1P and prevented CFTR downregulation (Figure 4 ). Neither HF nor etanercept treatment affected vasomotor responses to phenylephrine ( Figure 4C ), indicating specific effects on S1P signaling. To assess reversibility, we delayed etanercept treatment (ie, initiated a 2-week treatment at 6 weeks post-LAD ligation) and observed normalized CFTR expression ( Figure 4E ).
In accordance with the TNF-␣ sequestration results, HF failed to augment myogenic tone ( Figure 5A ) and vasomotor responses to S1P ( Figure 5B ) in PCAs isolated from TNF-␣ knockout (TNF Ϫ/Ϫ ) mice; intriguingly, phenylephrine responses in TNF Ϫ/Ϫ PCAs were enhanced at the 0.1-and 1-mol/L concentration in HF ( Figure 5C ). CFTR protein expression in the PCA did not change in HF ( Figure 5D ), which indicates that the CFTR downregulation observed in wild-type mice depends on TNF-␣ signaling. Similar observations for all parameters were made for mesenteric arteries isolated from TNF Ϫ/Ϫ mice ( Figure VI in the online-only Data Supplement).
Primary mouse VSMCs exposed to TNF-␣ (10 ng/mL, 24 hours) showed reductions in CFTR mRNA ( Figure VII in the online-only Data Supplement) and protein ( Figure 6A ) expression, with a concomitant reduction in their uptake of FITC-S1P ( Figure 6B ). The TNF-␣-mediated effects on CFTR expression and FITC-S1P uptake fully recovered within 24 hours after the removal of TNF-␣ ( Figure 6C and 6D). Of note, TNF-␣ induced a rapid decline in CFTR expression (t 1/2 ϭ6.5 hours, with significant differences ver- sus control by 9 hours; Figure 6E) . A subsequent analysis of the "B" (immature, nonglycosylated CFTR; 165 kDa) and "C" bands (mature, glycosylated CFTR; 170 kDa) 26, 27 indicated a loss of the mature form of CFTR (band C), which did not appear to result from reduced expression/maturation (band B; Figure 6E ). Assessment of membrane and intracellular fractions indicated a decline in membrane-associated CFTR without intracellular accumulation, consistent with the operation of a degrading mechanism ( Figure 6F ).
Brain, Heart, and Lung Tissues Also Show a HF-Induced, TNF-␣-Dependent Downregulation of CFTR Expression
HF reduces CFTR protein expression in the brain (by 41Ϯ3%; nϭ3), heart (by 18Ϯ1%; nϭ4 -5), and lung (by 34Ϯ4%; nϭ4 -8); systemic TNF-␣ sequestration with etanercept (treatment initiated immediately after the LAD ligation) prevents this downregulation ( Figure 7A through 7C) . Staining of lung slices with a CFTR antibody localized the majority of CFTR expression in terminal bronchioli to the epithelium ( Figure 7D ). 28 HF significantly reduces bronchial epithelia CFTR expression (by 34%; nϭ4; Figure 7E and 7F), a result that matches well with the Western blot data displayed in Figure 7C .
Discussion
The rheostat between S1P synthesis 29 and degradation 3 importantly contributes to the control of myogenic tone in resistance arteries. As an intrinsic, smooth muscle celldependent response to alterations in transmural pressure, myogenic tone is central to the local autoregulation of tissue perfusion and, at the systemic level, influences mean arterial pressure by dictating the magnitude of total peripheral resistance. A failure to adequately control the S1P rheostat within the microcirculation would therefore have significant detrimental vascular effects, evident at both the local and systemic levels.
We have demonstrated recently that SPP1 degrades extracellular S1P and thus is a physiologically relevant, endogenous regulator of myogenic tone. 3 However, the predominant intracellular localization of SPP1 necessitates an import mechanism in order for SPP1 to exert is regulatory function. This potentially imposes the transport process (ie, the mechanism shuttling extracellular S1P across the plasma membrane for degradation by SPP1) as the key regulatory and rate-limiting step in the S1P degradation chain. Indeed, the fact that there are few known regulators of SPP1 activity supports the view that the transporter, rather than SPP1, is the primary site of S1P degradation control. Previous investigations by us 3 and others 9 provide indirect evidence implicating CFTR in this transport process.
The present investigation identifies a direct pathophysiological link between CFTR and S1P signaling and introduces a novel, broadly applicable paradigm that resolves the issue of the manner in which extracellular S1P is ultimately degraded by intracellular S1P phosphatases. Within the S1P degradation pathway, CFTR acts as a molecular gatekeeper that is well positioned to regulate the entire process. Because S1P signaling plays a critical role in virtually every cell type and is known to be altered in several pathological settings, it is conceivable that CFTR dysregulation contributes to a range of immunologic, 10 cardiovascular, 11 and oncogenic 12 disorders with an S1P component. In this regard, our paradigm positions CFTR as a potential therapeutic target for these conditions.
Our investigation has also improved our understanding of mechanisms that regulate S1P signaling in resistance artery VSMCs. A traditional viewpoint favors increased S1P synthesis as the primary means of elevating S1P levels; although energy intensive, this mechanism clearly operates during Figure 6 . Tumor necrosis factor-␣ (TNF-␣) downregulates cystic fibrosis transmembrane conductance regulator (CFTR) expression and stimulates a reduction in plasma membrane-associated CFTR. A, TNF-␣ (10 ng/mL; 24 hours) stimulates the downregulation of mesenteric vascular smooth muscle cell CFTR protein expression (nϭ6), with (B) a concomitant reduction in fluorescein isothiocyanatesphingosine-1-phosphate (S1P) uptake (nϭ6). Both the reduced CFTR expression (nϭ4) (C) and attenuated fluorescein isothiocyanate-S1P uptake (nϭ4 -10) (D) were completely reversed 24 hours after TNF-␣ washout. E, TNF-␣ treatment (10 ng/mL) stimulates a steady decline in CFTR protein expression (nϭ4). Analysis of the 165-kDa (immature, nonglycosylated CFTR; band B) and 170-kDa (mature, glycosylated CFTR; band C) bands indicated that only the mature form of CFTR declined. F, Analysis of plasma membrane and intracellular fractions (nϭ6) indicated that membrane-associate CFTR was reduced without a concomitant accumulation of intracellular-associated CFTR. In A and B, *PϽ0.05 for unpaired comparisons with control (con)/background (Bkgd); in C through F, *PϽ0.05 for multiple, unpaired comparisons with the control value at timeϭ0 hours; ϩPϽ0.05 for difference between pre-TNF-␣ removal and TNF-␣ removal. acute myogenic vasoconstriction responses. 29 In contrast, enhancing S1P signaling through limited uptake/degradation via CFTR enables a system to maintain high levels of S1P signaling at a constant synthesis rate, with minimal energy cost. Indeed, our data demonstrate the effectiveness of inhibiting S1P degradation, and we speculate that this may be the preferred mechanism for sustained elevations of S1P signaling in chronic conditions such as HF.
In the present study, we demonstrate that perturbation of CFTR expression or localization significantly alters S1P signaling. Reducing plasma membrane CFTR abundance (genomic deletion [CFTR Ϫ/Ϫ ], downregulation after TNF-␣ treatment, and intracellular retention [CFTR ⌬F508 ]) augmented S1P signaling. In the case of the CFTR ⌬F508 mutant, we confirm that in order to transport extracellular S1P, CFTR must reside within the plasma membrane.
On the basis of the relationship between CFTR and S1P signaling we establish here, we would expect that the most widely recognized pathology associated with CFTR dysfunction, cystic fibrosis, should encompass vascular effects mediated by enhanced S1P signaling (in addition to or in conjunction with effects related to the other functions of CFTR, eg, chloride transport). Although cystic fibrosis is associated with cardiac impairment, 30, 31 it is not clinically associated with hypertension, a systemic effect that would be predicted as a consequence of S1P-dependent augmentation of myogenic tone and hence peripheral resistance. However, mean arterial pressure measurements integrate several factors and mechanisms (eg, blood volume, cardiac output, total peripheral resistance). In addition to cardiac dysfunction, 30, 31 patients with cystic fibrosis are known to have increased sweat salt loss 32 ; both are confounding factors that could ameliorate the effects of increased resistance artery tone. Nevertheless, our findings align well with previous studies reporting altered lipid metabolism in patients with cystic fibrosis (eg, accumulation of ceramide, 33 a lipid mediator involved in the sphingolipid rheostat 1 ).
To date, very little effort has been made to investigate S1P signaling in clinical or experimental cystic fibrosis. This may reflect the fact that the importance of CFTR in controlling S1P bioavailability has been largely underestimated. The present investigation clearly demonstrates that the genetic deletion of CFTR results in a marked enhancement of S1P-stimulated vasoconstriction and myogenic tone, observations that corroborate previous results utilizing a chemical CFTR inhibitor. 3 In the case of myogenic vasoconstriction, the enhancement was observed in 2 structurally and functionally distinct artery types (ie, mesenteric and cerebral resistance arteries), suggesting that this enhancement is not confined to 1 specific artery subtype. Taken together, our observations support the premise that CFTR is an integral element determining resistance artery homeostasis, with direct relevance under both physiological and potentially pathophysiological conditions. CFTR regulation, which includes expression, localization, and gating, is highly dynamic; changes in CFTR function/ expression could represent an important underlying component of several disease processes. In particular, the inflammatory mediator TNF-␣ is a negative regulator of CFTR, 34 -37 which tacitly involves CFTR in conditions that possess an inflammatory component. Remarkably, we have demonstrated previously that TNF-␣ augments resistance artery contractile function via an S1P-dependent mechanism, both when applied exogenously ex vivo 5, 38 and under the more relevant systemic inflammatory setting of HF. 5 Although we 38 and others 39 have also documented TNF-␣-dependent activation of sphingosine kinase 1, this mechanism alone cannot explain the leftward shift in the S1P dose-response relationship observed ( Figure 4B ). In fact, the augmented responses to exogenous S1P suggest either increased S1P 2 receptor function or impairment of S1P degradation as the underlying cause. In the absence of alterations to S1P 2 or SPP1 expression, the current data favor reduced CFTR expression and/or function as the primary underlying mechanism.
Our results suggest that TNF-␣ reversibly controls CFTR expression by both genomic and nongenomic mechanisms. In the short term, we observe a steady decline of membraneassociated CFTR, without intracellular accumulation ( Figure  6F ) or perturbation in the levels of immature CFTR ( Figure  6E ). This indicates that membrane-associated CFTR is degraded as opposed to sequestered. After 24 hours, reductions in CFTR mRNA are observed, suggesting genomic effects on transcription or mRNA stability.
The suppression of CFTR expression in concert with limiting membrane abundance occurs on a time scale that is compatible with both short-and long-term regulation of CFTR function. In our chronic model of HF, we observe a TNF-␣-dependent (ie, etanercept-sensitive) downregulation of CFTR that correlates with the enhancement of S1Pdependent effects on microvascular tone and with a reported reduction in cerebral blood flow. 5 Interrupting TNF-␣ signaling immediately after LAD ligation prevents the downregulation of CFTR, which subsequently enhances S1P signaling. Interrupting TNF-␣ signaling at later time points, after HF is fully established, restores CFTR expression and microvascular S1P signaling.
The same paradigm was observed in whole-organ lysates from brain, heart, and lung, which consistently demonstrated etanercept-sensitive CFTR downregulation in HF (Figure 7) . The fact that HF downregulates CFTR expression in terminal bronchioli epithelial cells, which differ from vascular smooth muscle in terms of both function and developmental origin, elevates the significance of our findings beyond that of the microvascular field. It is tempting to speculate that TNF-␣induced CFTR downregulation (see scheme in Figure 8 ) is a global response and a key underlying component driving multiorgan dysfunction in HF.
In summary, CFTR represents a bottleneck within the S1P degradation pathway that therefore controls S1P signaling. CFTR dysfunction therefore perturbs S1P signaling and, as such, could represent an underlying cause of pathogenic changes in S1P signaling (ie, CFTR is an upstream target in the disease process). In the present study, we present data suggesting that the reversible downregulation of CFTR enhances microvascular reactivity in HF, a critical determinant of disease progression. On the basis of this investigation, we conclude that CFTR represents an unexplored therapeutic target for conditions related to altered S1P signaling.
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We gratefully acknowledge the following funding support: operating and infrastructure grants from the Canadian Institutes of Health Figure 8 . Schematic representation of the proposed relationship between cystic fibrosis transmembrane conductance regulator (CFTR) and sphingosine-1-phosphate (S1P) signaling. S1P produced by sphingosine kinase 1 (Sphk1) is released to the extracellular compartment, where it (1) activates S1P receptor (S1PR)-dependent signaling pathways or (2) is transported by CFTR across the plasma membrane for degradation by S1P phosphohydrolase 1 (SPP1). During heart failure, tumor necrosis factor-␣ (TNF-␣) stimulates the downregulation of CFTR (3), thus inhibiting S1P degradation and concomitantly enhancing S1P receptor signaling. sER indicates smooth endoplasmic reticulum.
